---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-060230"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T18:36:45.698423+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MannKind Q3 total revenue $51M, up 56% YoY; net income $2M GAAP

## Summary
- Total revenue $51.3M, +56% YoY; net income $2M (GAAP); non-GAAP net income $4M.
- Tyvaso DPI royalties $20.2M, +225% YoY, driven by patient demand.
- Afrezza net revenue $13.5M, +24% YoY on higher demand and price; V-Go down 18%.
- Cash and investments $144.3M; R&D spending rose to $10M (vs $4.1M) on pipeline MNKD-101.
- Commercial product gross margin improved to 78% from 69% YoY.

## SEC filing metadata
- accession: 0000950170-23-060230
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/0000950170-23-060230-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/mnkd-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-060230
- JSON: https://secwatch.observer/filing/0000950170-23-060230.json
- Plain text: https://secwatch.observer/filing/0000950170-23-060230.txt

## Key facts
- Earnings Releases
  MANNKIND CORP reported quarter ended September 30, 2023 results: revenue Total revenues of $51M, net income Net income of $2M.
  - Period: quarter ended September 30, 2023
  - Revenue: Total revenues of $51M
  - Net income: Net income of $2M
  - Result: reported results
  source text: --- EX-99.1 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 • 3Q 2023 Net income of $2M; Non-GAAP net income of $4M • 3Q 2023 Tyvaso DPI royalties of $20M;
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000095017023060230/0000950170-23-060230-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.